baber/WOPTO huggingface dataset:
Patent BR-PI1008152-B1 (BR)
Title: método para identificar um dispositivo móvel conectado a uma rede para prover comunicação móvel
Inventor: PÄR THORSTENSSON
IPC: H04L29/06
Filed: 2010-03-26
Abstract: MÉTODO PARA IDENTIFICAR UM TELEFONE MÓVEL A presente invenção provê um método para identificar um telefone móvel, i.e. um dispositivo, incluindo um sistema ADD conectado à rede (2) para comunicação móvel, o sistema ADD compreendendo um TCD (3) tendo valores de perfil de terminal SAT armazenados para todos modelos de dispositivo (4). A _ presente invenção se caracteriza pelo fato de incluir as etapas de: recuperar o número IMEI do dispositivo (4); recuperar o modelo do dispositivo e perfil de terminal SAT (P2) do TCD (3) através do IMEI recuperado; obter perfil de terminal SAT (P1) do dispositivo verdadeiro (4); comparar o perfil de terminal SAT (P1) do dispositivo verdadeiro com o perfil de terminal SAT (P2) obtido a partir do TCD (3) no sistema ADD (1); e considerar o dispositivo (4) tendo o número IMEI certo no caso de o perfil de terminal SAT do dispositivo verdadeiro (P1) e o perfil de terminal SAT (P2) obtido a partir do TCD (3) coincidirem.
Patent BR-PI1011048-B1 (BR)
Title: plasmídeo independente de antibiótico
Inventor: EDMOND JOLIVET
IPC: C12N15/68
Filed: 2010-05-24
Abstract: plasmídeo independente de antibiótico a presente invenção fornece um método de manutenção de um plasmídeo de bactéria gram-negativa sem o uso de pressão de seleção de antibióticos. além disso, a invenção referese aos plasmídeos independente de fármaco produzidos, incluindo plasmídeos independente de fármaco contendo um gene heterólogo. a invenção também fornece formulações e/ou composições que compreendem os plasmídeos independente de fármaco que compreendem um gene heterólogo, formulações e/ou composições compreendendo uma proteína ou um imunógeno expresso utilizando os plasmídeos independente de fármaco, e métodos de administração de tais formulações e/ou composições a um hospedeiro. a invenção refere-se às bactérias gram-negativas contendo os plasmídeos independente de fármaco.
Patent BR-PI1106251-B1 (BR)
Title: sistema de bloqueio e dispositivo de comutação para sistema de bloqueio
Inventor: KLAUS WOLF
IPC: B64C25/26
Filed: 2011-09-28
Abstract: SISTEMA DE BLOQUEIO BEM COMO DISPOSITIVO DE COMUTAÇÃO PARA SISTEMA DE BLOQUEIO. A presente invenção refere-se a um sistema de bloqueio, especialmente um sistema de bloqueio para uma aeronave com ao menos um meio de bloqueio que pode ser transferido para ao menos uma primeira posição e para ao menos uma segunda posição, sendo que o sistema de bloqueio apresente ao menos um dispositivo comutador por meio do qual pode ser assegurado o alcance de uma posição terminal do meio de bloqueio e/ou possa ser controlado o sistema de bloqueio.
Patent EA-001363-B1 (EA)
Title: Crystalline pharmaceutical product
Inventor: ROSS STEPHEN TOREY
IPC: C07D401/14
Filed: 1997-08-29
Abstract: 1. (S)-7-[(4,4'-bipiperidin-1-yl)carbonyl]-2,3,4.5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid, hydrochloride. 2. The compound of claim 1 having a melting point of about 291 degree C. 3. The compound of claim 1 having a negative specific rotation of about 175. 4. A pharmaceutical composition comprising the compound of claim 1 and a pharmarceutically acceptable carrier. 5. The use of the compound of claim 1 in the manufacture of a medicament for inhibiting platelet aggregation. 6. A method of inhibiting platelet aggregration which comprises administering the compound of claim 1 to a mammal in need thereof. 7. A method of treating myocardial infarction, thrombosis, embolism, stroke and infarct-related disorders, or restenosis following angioplasty, which comprises administering the compound of claim 1. 8. A process for preparing the compound of claim 1 which comprises forming a solution of (S)-7-[(4,4'-bipiperidin-1-yl)carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid, hydrochloride and crystallizing said hydrochloride salt by precipitation or recrystallization.
Patent EA-003030-B1 (EA)
Title: Device for receiving seismic waves and method for coupling with a solid environment
Inventor: MEUNIER JULIEN
IPC: G01V1/20
Filed: 2001-02-09
Abstract: 1. A device for receiving seismic waves emitting from a solid environment (5) such as an underground zone comprising at least a hydrophone (2) arranged in a cavity (6) of the environment and coupled with it, characterized in that comprises a flexible-wall housing (7) destined for a tight coupling with the environment substantially by its entire surface and filled with liquid (8), the device comprises a hydrophone (2) immersed in a flexible-wall housing (7) which is closed at one end with a sealing plug (9) provided with a sealed duct for a cable (10) connecting the hydrophone with signal acquisition means (E). 2. The device of claim 1, characterized in that the closed housing (7) comprising a hydrophone (2) is closedly coupled with the environment preferably with a material capable of setting such as cement. 3. The device of claim 1, characterized in that comprises at least a geophone (1) coupled with the environment (7) proximate to the housing (7) containing the hydrophone (2) and coupled with signal acquisition means (E) 4. The device of claim 3, characterized in that the geophone (1) and the closed housing (7) comprising the geophone (1) are closed coupled with the environment injected with a material capable of setting such as cement. 5. A method for coupling a device for receiving seismic waves comprising at least a hydrophone (2) with a solid environment (5) such as an underground zone in which a cavity is arranged, characterized in that the hydrophone (2) immersed in a flexible-wall housing (7) filled with liquid (8) which is closed at one end with a sealing plug (9) provided with a sealed duct for a cable (10) connecting the hydrophone with signal acquisition means (E) for receiving signals and coupled by the housing entire surface with the environment by injecting a setting material such as cement into the cavity around the housing (7). 6. The method of claim 5, characterized in that comprising at least a geophone (1) proximate to the housing (7) containing the hydrophone (2) and coupled with the same setting material. 7. The method of claims 5 or 6, characterized in that the device is placed into a space between a wellbore and a tube descended into the wellbore and coupled it with the environment, injecting a material into at least one part of that space.
Patent EA-005595-B1 (EA)
Title: Method for separating zirconium and hafnium tetrachloride with the aid of a melted solvent
Inventor: DELONS LAURENCE
IPC: B01D3/40
Filed: 2002-04-12
Abstract: The invention relates to a method for separating zirconium and hafnium tetrachloride with the aid of a solvent comprising an alkaline metal solvent formed from an alkaline metal chloride salt and an acid metal chloride A, e.g. a chloroaluminate or an alkaline chloroferrate, and a metal chloride or an acid metaloid chloride B, whose acidity value is lower than that of the acid metal chloride A. The metal chloride or acid metalloid chloride B has an acidity value which is lower than that of the acid metal chloride A. The metal chloride or acid metalloid chloride B is preferably chosen from Mg, Zn and Cu chloride. The method can involve separation in a continuous manner, by selective absorption of the tetrachloride vapours by the solvent in a substantially or totally melted state.
Patent EA-007814-B1 (EA)
Title: Casein derived peptides and uses thereof in therapy
Inventor: SIDELMAN ZVI
IPC: A61P3/10
Filed: 2002-08-29
Abstract: Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the αS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases.
Patent EA-006531-B1 (EA)
Title: Method of soil and topography surveying
Inventor: ROONEY DANIEL JAMES
IPC: G01V11/00
Filed: 2002-10-24
Abstract: Methods of characterizing subsurface conditions in a selected geographic region (14) previously associated as a whole with a specific subsurface material characteristic reference profile such as from a USDA-NRCS soil survey. The method includes deploying a sensing tool (18,20) at selected positions (44) within the geographic region to determine a depth-referenced subsurface material characteristic such as soil type or strata, comparing the determined subsurface material characteristic to the subsurface material characteristic reference profile associated with the geographic region (14) to determine a correlation between the subsurface material characteristic reference profile and the depth-referenced subsurface material characteristic, and then deciding whether to deploy the tool at another position (44), and at what optimum position to deploy the tool, by considering the correlation.
Patent EA-009617-B1 (EA)
Title: Modified wheat flour for paper production and process therefor
Inventor: PLUSCHKE FRANK
IPC: C08K3/32
Filed: 2004-05-21
Abstract: The present invention relates to a modified cereal flour with improved suspension properties such as can be used for paper manufacture in particular and also a process for the production of the modified cereal flour and its use for paper manufacture.The present invention is particularly suitable for production of a modified cereal flour with improved suspension properties, which, therefor, in particular, can be more successfully used for paper manufacture.The present task is solved by using cereal crops containing grain flour and sodium metaphosphate, wherein the modified cereal flour can be obtained by extrusion of the flour and sodium metaphosphate.Sodium metaphosphate un the total formula Na[PO] n is 3, 4 or 5, most preferably n = 3.The modified cereal flour contains 0.5 to 3% by weight of sodium metaphosphate, wherein natural water content of the cereal flour is not calculated.The modified cereal flour contains 0.5 to 3% by weight of sodium metaphosphate, in particular, 0.5 to 3% by weight .The production of the modified cereal flour is by mixing the components with an extruder. A double-screw extruder is preferably used. All components, flour and SMP, are added to the extruder individually and/or mixed completely or partially with one another. Prior to extrusion water is usually also added.
Patent EA-009251-B1 (EA)
Title: Method of reducing the variance of signal-to-noise ratio estimate for a signal with differential phase and coherent amplitude modulation
Inventor: BLASCO CLARET JORGE VICENTE
IPC: G01R29/26
Filed: 2004-05-19
Abstract: The invention relates to a method of reducing the variance of a signal-to-noise ratio estimate for a signal with differential phase and coherent amplitude modulation. The invention is characterised in that, in order to calculate the samples of the noise power affecting the system, the amplitude and phase increment errors obtained at the receiver are combined, by shifting said errors (1) and (4) to the corresponding point of the first ring (6) of the constellation as if said ring had been transmitted and without undergoing any modification, in order subsequently to calculate the square of the modulus of the error vector (9). In this way, the invention minimises and equalises the variance of the samples obtained for the different even and odd values of bits for each carrier used by the system. In addition, the invention reduces the variance of the signal-to-noise ratio estimate in a multi-user digital communication system. The aforementioned estimate is necessary for selecting the number of bits per carrier, such that same can be adapted to the channel, as well as being necessary as support information when a diversity receiver is used.
Patent EA-008922-B1 (EA)
Title: Fungicidal mixtures
Inventor: TORMO I BLASCO JORDI
IPC: A01N43/90
Filed: 2004-09-14
Abstract: Disclosed are fungicidal mixtures containing as active components:1) a triazolopyrimidine derivative of formula (I),and2) metconazole of formula (II)at a synergistically effective quantity, methods for controlling harmful fungi that belong to the class of oomycetes with the aid of mixtures of compound (I) and compound (II), the use of compound (I) and compound (II) for producing such mixtures, and agents containing said mixtures.
Patent EA-011796-B1 (EA)
Title: Process and apparatus for recovery of non-ferrous metals from zinc residues
Inventor: VAN CAMP MAURITS
IPC: C22B4/00
Filed: 2004-08-30
Abstract: The invention relates to a process for the separation and recovery of non-ferrous metals from zinc-bearing residues, in particular from residues produced by the zinc manufacturing industry. The process comprises the steps of: vaporizing the residue in a blanket or in an agitated bath producing an Fe-bearing slag and Zn- and Pb-bearing fumes; and extracting the Zn- and Pb-bearing fumes and vaporizing Zn and Pb; the process is characterized in that CaO, SiOand MgO are added as a flux before or during the fuming step so as to obtain a final slag composition corresponding to the formula (1) wherein all concentrations are expressed in mass percent. The invention also relates to a single-chamber reactor for fuming Zn equipped with one or more submerged plasma torches as heat and gas sources.
Patent EA-016464-B1 (EA)
Title: Polycyclic arylimidazole derivative
Inventor: KIMURA TEIJI
IPC: A61K31/4178
Filed: 2007-03-08
Abstract: Disclosed is a compound represented by the formula (IA):or a pharmacologically acceptable salt thereof: (I) wherein Arrepresents a phenyl group or a pyridinyl group that may be substituted with a halogen atom or Calkoxy group, Rand Rrepresent a hydrogen atom and a halogen atom, and Het represents a 5-membered aromatic heterocyclic group comprising an optionally fused imidazole or triazole. The compound or the salt is effective as a therapeutic or prophylactic agent for a disease associated with Aβ.
Patent EA-018030-B1 (EA)
Title: Human binding molecules having killing activity against staphylococci and use thereof
Inventor: THROSBY MARK
IPC: A61K39/40
Filed: 2007-06-05
Abstract: The present invention provides human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from Staphylococcus.
Patent EA-014065-B1 (EA)
Title: Agent exhibiting properties to form the cellular immunity against mycobacterium tuberculosis h37 rv, method for the production thereof (variants), a recombinant strain and an agent for tuberculosis diagnosis
Inventor: KISLICHKIN NIKOLAY NIKOLAEVICH
IPC: A61K39/04
Filed: 2008-04-29
Abstract: The invention relates to biopharmacology, preparative biochemistry and medicine, in particular to an agent which is based on a tuberculous complex produced by a microorganism and which can be used for tuberculosis prevention, treatment and diagnosis. The recombinant 2-9XL Acinetobacter johnsonii strain, which is harmless for man, animal and environment, comprises, in the composition of the chromosome thereof, the fragment(s) of a chromosomal DNA M. tuberculosis H37 Rv, which makes it possible to simultaneously synthesise several proteins for forming a stable species-specific tuberculous glycoprotein complex in the outer membrane and capsular substance of a bacterium. Ease of use of the recombinant 2-9XL strain, the use of standard media, the stability of the species-specific tuberculous complex synthesis, the cost-effective and safe practice for releasing and purifying the tuberculous complex render said microorganism a potential producer of the agent exhibiting properties to form the T- and B-cellular immunity against an M. tuberculosis originator.
Patent EA-016276-B1 (EA)
Title: Method of calcium sulphate phosphosemihydrate processing
Inventor: DAVYDENKO VLADIMIR VASILIEVICH
IPC: C01F11/46
Filed: 2010-01-14
Abstract: The invention relates to recycling of wastes of extraction phosphoric acid production - calcium sulphate phosphosemihydrate into calcium sulphate dihydrate formed as a strong monolithic mass (phosphogypsum stone) used in cement industry as a regulator of cement setting time instead of using natural gypsum stone. Wherein the inventive method relates to processing wastes of extraction phosphoric acid production produced by a single-stage semihydrate method. A method of recycling calcium sulphate phosphosemihydrate - wastes of extraction phosphoric acid production into calcium sulphate dehydrate, including mixing phosphosemihydrate with lime component and further compaction of obtained mixture. Calcium sulphate phosphosemihydrate, obtained in production of extraction phosphoric acid by means of single-stage semihydrate method, is mixed in mixer with dry lime, which is supplied in amount 10-30 kg in terms of CaO per 1 t of phosphosemihydrate, mixing is carried out until mixture pH equal to 11-12 is reached, compaction is carried out layer-by-layer, value of each layer constituting 30-50 cm, calcium sulphate dihydrate being obtained in form of strong monolithic mass.
Patent EA-022310-B1 (EA)
Title: Salt forms of organic compound
Inventor: SIEGER PETER
IPC: C07D473/04
Filed: 2009-12-22
Abstract: The present invention relates to novel salt forms of 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)xanthine, a DPP-4 inhibitor and their use in pharmaceutical compositions useful in the treatment of type 2 diabetes, as well as their production.
Patent EA-029018-B1 (EA)
Title: Controlled release pharmaceutical formulations of nitazoxanide
Inventor: ROSSIGNOL JEAN-FRANCOIS
IPC: A61K31/495
Filed: 2010-02-12
Abstract: Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a controlled release portion comprising a first quantity of nitazoxanide or a salt, polymorph, ester or amide thereof, and a binder that is a low-viscosity polymer; and (b) an immediate release portion comprising a second quantity of nitazoxanide or a salt, polymorph, ester or amide thereof, wherein the low-viscosity polymer is selected from the group consisting of hydroxypropylmethylcellulose polymers and hydroxyethylcellulose polymers. A method of using the formulations in the treatment of hepatitis C is also provided.
Patent EA-026012-B1 (EA)
Title: Process for the manufacture of a multilayer material sheet, multilayer material sheet and use thereof
Inventor: PUTTEN VAN KOEN
IPC: B32B5/28
Filed: 2010-12-16
Abstract: The invention relates to a process for the manufacture of a multilayer material sheet comprising unidirectional high performance fibers, the process comprising the steps of positioning the fibers in a parallel fashion, consolidation of the fibers to obtain a monolayer, stacking at least two monolayers such that the fiber direction in one monolayer is at an angle α to the direction of the fibers in an adjacent monolayer and fixation whereby the stack of at least two monolayers is subjected to a pressure and temperature treatment for a duration of a least 2 seconds, followed by cooling the stack under pressure to a temperature of 120°C or lower.
Patent EA-025175-B1 (EA)
Title: Photodynamic therapy device for delivery of a photoactivatable composition to a treatment site
Inventor: PIERGALLINI REMIGIO
IPC: A61N5/06
Filed: 2010-10-27
Abstract: There is provided an applicator cartridge for delivery of a photoactivatable composition to a treatment site, having an applicator head and a reservoir adapted to receive the composition, which may be used with a photodynamic therapy device comprising an illuminating member. Methods of using the applicator cartridge and the device are also provided.
Patent EA-025510-B1 (EA)
Title: Oil-based grouting composition with an insulating material
Inventor: FRANTZ ERIC B
IPC: C09K8/467
Filed: 2011-06-14
Abstract: According to an embodiment, a method for thermally insulating a portion of a tubular located inside an enclosed conduit comprises the steps of: (A) introducing a grouting composition into an annulus between the tubular and the enclosed conduit, the grouting composition comprising: (i) an oil-swellable binding material; (ii) a hydrocarbon liquid, wherein the hydrocarbon liquid is the continuous phase of the grouting composition; and (iii) an insulating material comprising a hollow microsphere; and (B) allowing or causing the grouting composition to set after the step of introducing, wherein after setting the grouting composition has a thermal conductivity of less than 0.3 BTU/hr∙ft∙°F (0.5 w/m∙°C). According to another embodiment, a grouting composition for use in insulating a portion of a tubular located inside an enclosed conduit comprises: (A) an oil-swellable binding material comprising a organophilic clay; (B) a hydrocarbon liquid, wherein the hydrocarbon liquid is the continuous phase of the grouting composition; and (C) an insulating material comprising a hollow microsphere, wherein after the grouting composition has set, the grouting composition has a thermal conductivity of less than 0.3 BTU/hr∙ft∙°F (0.5 w/m∙°C).
Patent EA-025151-B1 (EA)
Title: Inhibitors of hepatitis c virus
Inventor: ZHONG MIN
IPC: A61K31/35
Filed: 2011-10-21
Abstract: A class of compounds having the structurethat inhibit Hepatitis C Virus (HCV) is disclosed, along with compositions containing these compounds, and methods of using these compositions for treating individuals infected with HCV.
Patent EA-027801-B1 (EA)
Title: Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
Inventor: BHAT SREENIVAS S
IPC: A61P29/00
Filed: 2012-12-26
Abstract: Dosage forms comprising (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dioneor a pharmaceutically acceptable salt thereof in an amount of 5 25 wt.% and a coating comprising polyvinyl alcohol are provided herein. Also provided is a dosage form suitable for oral administration, particularly a tablet. Also disclosed is a method of treating, preventing or managing psoriasis, arthritis, dermatitis, acne, dermatomyositis, ulcerative colitis, Behcet's disease, Crohn's disease, sarcoidosis, uveitis, rosacea or lichen planus by administering said dosage forms.
Patent EA-027327-B1 (EA)
Title: Flow control device and method
Inventor: MATHIESEN VIDAR
IPC: E21B43/32
Filed: 2013-03-06
Abstract: The invention relates to the field of producing hydrocarbons and, more specifically, to a device and a method of controlling the flow of fluids having different properties. A fluid flow control device comprises a housing having a fluid inlet (7) and at least one fluid outlet (8). A first fluid flow restrictor (1) serves as an inflow port to a chamber (B) in the housing, and a second fluid flow restrictor (2) serves as an outflow port from the chamber (B). The first fluid flow restrictor and the second fluid flow restrictor are configured to generate different fluid flow characteristics; and the chamber (B) comprises actuating means (5a-I) that is responsive to fluid pressure changes (ΔP) in the chamber. The first fluid flow restrictor (1) and the second fluid flow restrictor (2) are configured to impose its respective different fluid flow characteristics based on different fluid properties. In use, the invented fluid flow control device may be used to control fluid flow (F) through the housing, by allowing at least a portion (f) of the fluid (F) to flow through the first fluid flow restrictor (1) into the chamber (B) and out of the chamber via the second fluid flow restrictor (2); and utilizing the pressure change (ΔP) in the chamber that occurs when a property of the fluid changes to operate a valve device.